Stock listing

OTC:ORGS Orgenesis Inc. Stock

Follow Orgenesis Inc. into a list and get an email when it puts out news.

Share price · OTC:ORGS

$0.02 USD +0.02 (+900.0%)

Close on Nov 18, 2026

Past year -95.0% · daily closes, Jul 21, 2026 – Nov 18, 2026, adjusted for splits
Day range
$0.02 – $0.315 USDNov 18, 2026
Volume
250 sharesNov 18, 2026
Market cap
—Left out: price × shares is far from the company's reported size
Traded on an average day
$167 USDMedian day 101 shares · 5 days with no trades · last 3 months, Aug 18, 2026 – Nov 18, 2026
Orgenesis Inc. logo

Daily closes

Last 3 months, Aug 18, 2026 – Nov 18, 2026 · OTC:ORGS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.02+0.018+900.0%$0.315$0.315$0.02250
$0.0020-0.328-99.4%$0.30$0.33$0.00041,975
$0.33-0.045-12.0%$0.30$0.33$0.301,262
$0.375+0.075+25.0%$0.375$0.375$0.375110
$0.300.000.0%$0.30$0.30$0.30100
$0.300.000.0%$0.346$0.346$0.01429
$0.30-0.05-14.3%$0.30$0.30$0.30100
$0.350.000.0%$0.35$0.35$0.35100
$0.35-0.05-12.5%$0.35$0.35$0.35100
$0.40-0.09-18.4%$0.49$0.49$0.037900
$0.49+0.14+40.0%$0.49$0.49$0.49100
$0.350.000.0%$0.35$0.35$0.350
$0.350.000.0%$0.35$0.35$0.350
$0.350.000.0%$0.35$0.35$0.350
$0.350.000.0%$0.35$0.35$0.350
$0.35-0.20-36.4%$0.35$0.35$0.35200
$0.55-0.03-5.2%$0.55$0.55$0.55100
$0.58+0.03+5.5%$0.067$0.58$0.067357
$0.550.000.0%$0.55$0.55$0.55100
$0.55-0.03-5.2%$0.55$0.55$0.55100
$0.58-0.088-13.1%$0.58$0.58$0.58150
$0.668+0.167+33.5%$0.668$0.668$0.668100
$0.50-0.08-13.8%$0.50$0.50$0.50140
$0.58-0.01-1.7%$0.58$0.58$0.58100
$0.590.000.0%$0.59$0.59$0.59100
$0.59+0.168+39.7%$0.59$0.59$0.59100
$0.422-0.168-28.4%$0.41$0.422$0.412,838
$0.59-0.079-11.9%$0.59$0.59$0.59100
$0.669+0.079+13.5%$0.669$0.669$0.669100
$0.59+0.24+68.6%$0.59$0.59$0.59102
$0.350.000.0%$0.35$0.35$0.033400
$0.35-0.10-22.2%$0.35$0.35$0.35100
$0.45+0.038+9.1%$0.45$0.45$0.45102
$0.412+0.062+17.8%$0.05$0.412$0.051,127
$0.350.000.0%$0.35$0.35$0.35100
$0.350.000.0%$0.57$0.57$0.0338,530
$0.35+0.24+218.2%$0.35$0.35$0.35100
$0.11+0.077+236.4%$0.11$0.59$0.11286
$0.0330.000.0%$0.033$0.37$0.0332,767
$0.033-0.067-67.3%$0.79$0.79$0.0331,100
$0.100.000.0%$0.10$0.10$0.100
$0.10+0.067+205.8%$0.10$0.10$0.10239
$0.033-0.267-89.1%$0.595$0.595$0.033300
$0.30-0.05-14.3%$0.30$0.30$0.30115

Splits

3 splits since 2011 · OTC:ORGS · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
1-for-12Consolidation
35-for-1Split
Ticker
OTC:ORGS
Asset type
Stock
Exchange
OTC
Currency
USD

Orgenesis Inc. on 6ix

Calls
9 calls with a replay · 9 with a transcript · latest Aug 11, 2023
Decks
11 decks · latest Aug 29, 2024

Valuation

price Nov 18, 2026

Enterprise value
No market cap
P/E
No market cap
EV/sales
No market cap
EV/EBITDA
No market cap
Price/book
No market cap
Gross margin
No statements on 6ix yet
Operating margin
No statements on 6ix yet
Net margin
No statements on 6ix yet
Debt to equity
No statements on 6ix yet
Beta vs S&P 500
1.54

Team and board

OfficerRole
Vered CaplanChief Executive Officer of Orgenesis Inc.
Victor MillerChief Financial Officer of Orgenesis

Events

Calls

CallWhenStatus
Orgenesis (OTC:ORGS) Q2 2023 Earnings CallFri, Aug 11, 2023 · 8:00 AM ETReplay
Orgenesis (OTC:ORGS) Q4 2022 Earnings CallTue, Mar 21, 2023 · 11:00 AM ETReplay
Orgenesis (OTC:ORGS) Q3 2022 Earnings CallFri, Nov 11, 2022 · 8:00 AM ETReplay
Orgenesis (OTC:ORGS) Q2 2022 Earnings CallTue, Aug 16, 2022 · 11:00 AM ETReplay
Orgenesis (OTC:ORGS) Q4 2021 Earnings CallWed, Mar 30, 2022 · 12:00 PM ETReplay
Orgenesis (OTC:ORGS) Q3 2021 Earnings CallThu, Nov 04, 2021 · 8:30 AM ETReplay
Orgenesis (OTC:ORGS) Q2 2021 Earnings CallThu, Aug 05, 2021 · 8:30 AM ETReplay
Orgenesis (OTC:ORGS) Q1 2021 Earnings CallFri, May 07, 2021 · 8:30 AM ETReplay
Orgenesis (OTC:ORGS) Q4 2020 Earnings CallTue, Mar 09, 2021 · 8:30 AM ETReplay

Results days

QuarterResults
Q3 2024Nov 11, 2024 · Before open
Q2 2024Aug 8, 2024 · After close
Q1 2024May 20, 2024 · After close
Q3 2023Nov 13, 2023 · After close
Q2 2023Aug 10, 2023 · After close
Q1 2023May 10, 2023 · After close
Q4 2022Mar 22, 2023 · After close
Q3 2022Nov 10, 2022 · After close
Q2 2022Aug 15, 2022 · After close
Q1 2022May 23, 2022 · After close
All 15 quarters
QuarterResults
Q4 2021Mar 30, 2022 · Before open
Q3 2021Nov 4, 2021 · After close
Q2 2021Aug 5, 2021 · After close
Q1 2021May 6, 2021 · After close
Q4 2020Mar 9, 2021 · After close

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2024)Investor deck18 slidesAug 29, 2024
Investor Presentation (May 2024)Investor deck22 slidesMay 2024
Investor Presentation (July 2022)Investor deck29 slidesJuly 2022
Investor Presentation (April 2022)Investor deck32 slidesApril 2022
Investor Presentation (February 2022)Investor deck32 slidesFebruary 2022
Investor Presentation (2021)Investor deck23 slidesFeb 5, 2021
Investor Presentation (November 2020)Investor deck23 slidesNov 12, 2020
Corporate Update (May 2020)Corporate update9 slidesMay 6, 2020
Investor Presentation (October 2018)Investor deck28 slidesOct 29, 2018
Investor Presentation (July 2018)Investor deck20 slidesJul 20, 2018
All 11 decks
DeckKindSlidesDate
Investor Presentation (January 2018)Investor deck34 slidesJan 9, 2018

Open Decks

Financials

Annual, in USD

Income statement

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2018FY2017FY2016
Revenue1.03M530.0K36.0M35.5M7.65M33.3M18.7M18.7M10.1M6.40M
Cost of revenue9.51M6.25M20.4M28.2M31.1M18.1M10.7M10.7M6.81M7.66M
Gross profit-8.47M-5.72M15.6M7.34M-23.4M15.1M7.96M7.96M3.28M-1.26M
Research and development3.84M11.1M6.01M36.6M84.0M12.5M6.46M6.46M2.48M2.16M
Selling, general and administrative12.9M34.6M16.2M15.4M19.4M25.3M16.6M16.6M10.7M6.45M
Operating income-26.1M-53.6M-7.54M-16.8M-95.8M-24.6M-14.7M-14.7M-11.2M11.3M
Depreciation and amortization2.09M1.56M1.98M1.86M1.44M3.81M2.62M2.62M2.60M2.92M
EBITDA-24.0M-52.1M-5.56M-14.9M-94.3M-20.8M-12.0M-12.0M-8.63M14.2M
Interest expense3.74M2.17M1.82M369.0K1.09M461.0K2.75M2.75M1.23M689.0K
Income before tax-48.9M-64.4M-12.0M-18.0M-96.7M-25.5M-17.8M-17.8M-13.7M-10.7M
Income tax473.0K209.0K108.0K-1.61M563.0K1.34M1.34M-1.31M-1.55M
Net income-48.2M-55.4M-14.9M-18.1M-95.8M-26.0M-18.3M-18.3M-12.4M-9.19M
Earnings per share, basic-9.31-1.91-0.59-0.74-4.49-1.64-1.37-1.37-1.27-1.08

Balance sheet

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2018FY2017FY2016
Cash and equivalents78.0K837.0K5.31M5.47M44.9M11.4M16.1M16.1M3.52M891.0K
Short-term investments152.0K
Receivables40.0K2.56M39.8M19.7M3.25M2.04M11.2M11.2M2.21M2.13M
Inventory034.0K120.0K118.0K185.0K2.04M1.74M1.74M725.0K400.0K
Current assets761.0K4.08M46.3M25.8M50.1M26.0M30.3M30.3M7.29M4.21M
Property, plant and equipment5.11M4.27M3.03M12.5M11.9M5.10M4.57M
Goodwill01.21M8.19M8.40M8.74M14.9M15.2M15.2M10.7M9.58M
Total assets1.35M14.6M90.9M59.8M77.7M92.5M75.4M75.4M39.9M33.5M
Accounts payable10.4M6.58M4.43M5.24M8.65M5.55M3.80M3.80M3.91M4.55M
Current liabilities26.9M16.4M15.9M15.4M16.3M31.6M17.1M17.1M16.9M14.6M
Long-term debt8.47M19.0M13.3M4.85M7.26M13.4M2.85M2.70M4.53M4.35M
Total debt22.6M20.3M11.8M12.9M24.8M3.73M3.73M7.69M9.84M
Total liabilities38.9M35.5M31.7M21.2M25.0M86.4M46.8M46.8M25.7M22.9M
Shareholders' equity-37.5M-21.0M27.6M38.5M52.6M5.48M28.4M28.6M14.1M10.6M
Shares outstanding5.17M29.0M25.1M24.3M21.3M15.9M13.4M13.4M9.71M8.52M

Cash flow

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2018FY2017FY2016
Cash from operations-17.1M-14.8M-24.9M-26.9M-78.0M-13.2M-15.7M-15.7M-3.83M-3.78M
Capital spending-263.0K-2.10M-12.4M-7.87M-1.52M-12.1M-5.56M-5.56M-975.0K-1.43M
Free cash flow-17.3M-16.9M-37.3M-34.7M-79.6M-25.3M-21.2M-21.2M-4.81M-5.21M
Cash from investing-3.71M-14.1M-12.4M105.6M-13.8M-6.27M-6.27M-3.40M-1.54M
Cash from financing16.0M13.6M39.6M-106.0K5.88M24.1M35.1M35.1M8.37M2.12M
Dividends paid-106.0K
Share buybacks-107.0K-1.02M-250.0K13.2M17.4M5.30M1.49M
Change in cash-752.0K-4.89M395.0K-39.6M33.5M-2.96M12.9M12.9M2.63M-3.28M

Open Financials

Cap table

Built by 6ix from Orgenesis Inc.’s releases

Common shares
9,799,538
Fully diluted
9,799,538

Fully diluted

LineShares
Common shares9,799,538

Share count over time

CountShares
Nov 22, 20269,799,538

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David Sidransky
Other companies: Ascentage Pharma Group International (Independent non-executive Director · Since at least Mar 18, 2026); Galmed Pharmaceuticals Ltd. (Lead Independent Director · Since at least Mar 18, 2026); Champions Oncology, Inc. (Lead Director · Since at least Aug 28, 2009); Cactus Acquisition Corp. 1 Limited (Director · Oct 28, 2021 – Oct 28, 2021 · Past); Ayala Pharmaceuticals Inc (Director · May 7, 2020 – Jan 19, 2023 · Past); Akari Therapeutics PLC (Director · Jan 1, 2015 – Jan 1, 2015 · Past); Immune Pharmaceuticals Inc (Director · Oct 10, 2013 – Jan 8, 2015 · Past); Advaxis Inc (Director · Jul 16, 2013 – May 4, 2020 · Past); Zila Inc (Director · Oct 24, 2006 – Jan 9, 2007 · Past)
Director · Oct 22, 2018 – Dec 20, 2023 · Past
Elliot Maltz
Other companies: Alimera Sciences Inc (Chief Financial Officer · Jan 2, 2024 – Sep 16, 2024 · Past)
Chief Financial Officer · Sep 1, 2023 – Sep 4, 2023 · Past
Adam PelavinDirector · Oct 28, 2024 – Dec 12, 2024 · Past
Ashish NandaDirector · Dec 23, 2022 – Dec 12, 2024 · Past
Chris Georges Frans BuyseDirector · Mar 2, 2015 – Mar 2, 2015 · Past
Denis BedoretSee Remarks · May 14, 2018 – Mar 5, 2019 · Past
Dov WeinbergCFO, Secretary & Treasurer · Feb 2, 2012 – Feb 2, 2012 · Past
Guy YachinDirector · Oct 22, 2018 – Dec 20, 2023 · Past
Itzhak ViderDirector · Jul 8, 2024 – Dec 12, 2024 · Past
Jacob BenairiePresident & CEO · Feb 2, 2012 – Feb 2, 2012 · Past
All 21 people
PersonSeat
Jagannathan BhalajiDirector · Oct 28, 2024 – Dec 12, 2024 · Past
Kunik Efrat AssaChief Development Officer · Dec 15, 2021 – Jun 14, 2022 · Past
Mario PhilipsDirector · Jan 9, 2020 – Dec 20, 2023 · Past
Mark GoodmanDirector · Jun 27, 2024 – Jun 27, 2024 · Past
Neil ReithingerCFO, Treasurer and Secretary · Mar 5, 2019 – Jun 14, 2022 · Past
Santhosh NagarajDirector · Oct 28, 2024 – Dec 12, 2024 · Past
Sarah FerberChief Scientific Officer · Feb 2, 2012 – Mar 19, 2020 · Past
Sav DiPasqualePresident and CEO · Dec 17, 2012 – Dec 17, 2012 · Past
Vered CaplanChief Executive Officer of Orgenesis Inc. · Since at least Nov 30, 2016
Victor MillerChief Financial Officer of Orgenesis · Since at least Jan 2, 2024
Yaron AdlerDirector · Dec 31, 2021 – Dec 12, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Orgenesis Inc.